Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy

Severe asthma greatly affects patients’ quality of life. Major advances have occurred in the management of severe eosinophilic asthma the past few years due to the new targeted biological therapies. There are three anti-IL-5 mAbs, mepolizumab, reslizumab and benralizumab. Despite the different mecha...

Full description

Bibliographic Details
Main Authors: Agamemnon Bakakos, Nikoleta Rovina, Petros Bakakos
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:International Journal of Molecular Sciences
Subjects:
asthma
severe eosinophilic asthma
anti-IL-5
anti-IL-5R
mepolizumab
benralizumab
Online Access:https://www.mdpi.com/1422-0067/22/8/3969

Similar Items

Similar Items